mitoquinone | 336184-91-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: mitoquinone
• 英文别名: 2-(10-triphenylphosphoniumdecyl)-3-methyl-5,6-dimethoxy-1,4-benzoquinone bromide；mitoQ10；[10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]-triphenylphosphonium bromide；MitoQ；Mitoquinone bromide；10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium;bromide
• CAS: 336184-91-9
• 化学式: Br*C₃₇H₄₄O₄P
• 分子量: 663.632
• InChiKey: DMRUQISFVFDWGE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  4.47
• 重原子数：
  43
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(10-溴癸基)-5,6-二甲氧基-3-甲基-1,4-苯二酚 、 三苯基膦 在 乙醇 、 水 、 甲醇 、 palladium 10% on activated carbon 、 氧气 作用下， 反应 72.0h， 以92%的产率得到mitoquinone
  参考文献：
  名称：

  Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria

  摘要：

  Analogues of mitoQ and idebenone were synthesized to define the structural elements that support oxygen consumption in the mitochondrial respiratory chain. Eight analogues were prepared and fully characterized, then evaluated for their ability to support oxygen consumption in the mitochondrial respiratory chain. While oxygen consumption was strongly inhibited by mitoQ analogues 2-4 in a chain length-dependent manner, modification of idebenone by replacement of the quinone methoxy groups by methyl groups (analogues 6-8) reduced, but did not eliminate, oxygen consumption. Idebenone analogues 6-8 also displayed significant cytoprotective properties toward cultured mammalian cells in which glutathione had been depleted by treatment with diethyl maleate. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.104

文献信息

• METHODS FOR REDUCING ANTHRACYCLINE-INDUCED TOXICITY
  申请人：Kalyanaraman Balaraman

  公开号：US20080032940A1

  公开（公告）日：2008-02-07

  Methods for treating cancers/tumors, including administering to a subject an effective amount of a mitochondria-targeted antioxidant alone or in combination with a chemotherapeutic agents. Likewise, methods for mitigating toxicity associated with a chemotherapeutic agent including administering an effective amount of a mitochondria-targeted antioxidant with a single or with multiple chemotherapeutic agents.

  治疗癌症/肿瘤的方法，包括向受试者单独或与化疗药物联合使用线粒体定向抗氧化剂的有效剂量。同样，减轻与化疗药物相关的毒性的方法包括使用单个或多个化疗药物与线粒体定向抗氧化剂的有效剂量。
• MITOCHONDRIALLY TARGETED ANTIOXIDANTS IN THE TREATMENT OF LIVER DISEASES AND EPITHELIAL CANCERS
  申请人：Oridis Biomed Forschungs- und Entwicklungs GmbH

  公开号：EP1765413A2

  公开（公告）日：2007-03-28
• Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease
  申请人：Buck Charles

  公开号：US20070161609A1

  公开（公告）日：2007-07-12

  The present invention relates to the method of treatment or prophylaxis of patients with drug-induced liver diseases which comprises administering to the patient in need thereof a therapeutically effective amount of a mitochondrially targeted antioxidant compound e.g. derivatives of vitamin E, coenzyme Q 10 or a glutathione peroxidase mimetic. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use.
• Use of Mitochondrially Targeted Antioxidant in the Treatment of Liver Diseases and Epithelial Cancers
  申请人：Frohlich Eleonore

  公开号：US20070225255A1

  公开（公告）日：2007-09-27

  The present invention relates to the use of a mitochondrially targeted antioxidant, e.g. derivatives of vitamin E, coenzyme Q 10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and/or epithelial cancers. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use. Furthermore the invention relates to the manufacture of medicaments containing the antioxidant(s) useful for such prevention and treatment.
• COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS
  申请人：Jurkunas Ula V.

  公开号：US20130288985A1

  公开（公告）日：2013-10-31

  This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention.